Septerna, Inc.
SEPNHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Septerna, Inc. focuses on Biotechnology services and products. Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products for the treatment of endocrinology, immunology and. At a $1.51B market cap, Septerna, Inc. ranks as a small-cap company within healthcare. It develops PTH1R Program, oral small molecule Parathyroid Hormone 1 Receptor agonists for the treatment of hypoparathyroidism; SEP-631, an oral small molecule MRGPRX2 negative allosteric modulator (NAM) for chronic spontaneous urticaria and other mast cell diseases; and TSHR Program, an oral small molecule TSHR NAM for graves' disease and thyroid eye disease.
Market Cap
$1.51B
Beta
—
P/E (TTM)
—
P/E (Fwd)
-12.56
EPS (TTM)
$-0.84
EPS (Fwd)
$-2.66
ROE
-9.3%
ROA
-8.5%
Cash
$347.4M
Total Debt
$23.1M
Free CF
$24.0M
52W Change
166.1%
Annual Financials
Cash vs Debt
With $347.4M in cash and $23.1M in debt, SEPN maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. Free cash flow comes in at $24.0M, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. Return on equity stands at -9.3%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing SEPN.